Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1161/JAHA.115.002790 http://scihub22266oqcxt.onion/10.1161/JAHA.115.002790 C4859398!4859398!26722127     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 247.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 247.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 247.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 247.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Am+Heart+Assoc 2016 ; 5 (1): ä Nephropedia Template TP {{tp|p=26722127|t=2016. Comparison of Basiliximab and Anti?Thymocyte Globulin as Induction Therapy in Pediatric Heart Transplantation: A Survival Analysis |pdf=|usr=}}{{26722127}} gab.com Text Comparison of Basiliximab and Anti Thymocyte Globulin as Induction Therapy in Pediatric Heart Transplantation: A Survival Analysis JO: J Am Heart Assoc http://www.kidney.de/pget.php?&tw=1&pmid=26722127 #FOAvip Background: Basiliximab and anti?thymocyte globulin are widely used drugs for induction therapy after pediatric heart transplantation. The aim of this study was to determine whether any differences could be observed between basiliximab and anti?thymocyte globulin, with respect to long?term mortality, in a population of pediatric cardiac transplant recipients. Methods and Results: An analysis of pediatric heart transplant patients (aged <18 years) from the United Network for Organ Sharing database was conducted that compared patients receiving basiliximab with those that received anti?thymocyte globulin for the risk of all?cause mortality. Secondary endpoints included death attributable to graft failure, cardiovascular causes, infection, or malignancy. Of the 2275 patients, 685 received basiliximab and 1590 anti?thymocyte globulin. One?year survival was similar for both groups; however, at 5 and 10 years, basiliximab was associated with poorer long?term survival (68% versus 76% at 5 years [P<0.001] and 49% versus 65% at 10 years [P<0.001], respectively). Basiliximab was associated with higher risk of death attributable to graft failure (P=0.013), but not death attributable to cardiovascular causes (P=0.444), infection (P=0.095), or malignancy (P=0.392). After multivariate analysis, use of basiliximab (versus use of anti?thymocyte globulin) remained significantly associated with all?cause mortality (hazard ratio, 1.27; 95% confidence interval, 1.02?1.57; P=0.030). Conclusions: In pediatric heart transplant patients, use of basiliximab for induction therapy was associated with an increased risk of mortality, when compared with those receiving anti?thymocyte globulin. Twit Text FOAVip Comparison of Basiliximab and Anti Thymocyte Globulin as Induction Therapy in Pediatric Heart Transplantation: A Survival Analysis ????J Am Heart Assoc http://www.kidney.de/pget.php?&tw=1&pmid=26722127 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26722127 #FOAvip English Wikipedia <ref>{{Cite pmid|26722127}}</ref> Comparison of Basiliximab and Anti?Thymocyte Globulin as Induction Therapy in Pediatric Heart Transplantation: A Survival Analysis #MMPMID26722127 Ansari D; Höglund P; Andersson B; Nilsson J J Am Heart Assoc 2016[Jan]; 5 (1): ä PMID26722127show ga Background: Basiliximab and anti?thymocyte globulin are widely used drugs for induction therapy after pediatric heart transplantation. The aim of this study was to determine whether any differences could be observed between basiliximab and anti?thymocyte globulin, with respect to long?term mortality, in a population of pediatric cardiac transplant recipients. Methods and Results: An analysis of pediatric heart transplant patients (aged <18 years) from the United Network for Organ Sharing database was conducted that compared patients receiving basiliximab with those that received anti?thymocyte globulin for the risk of all?cause mortality. Secondary endpoints included death attributable to graft failure, cardiovascular causes, infection, or malignancy. Of the 2275 patients, 685 received basiliximab and 1590 anti?thymocyte globulin. One?year survival was similar for both groups; however, at 5 and 10 years, basiliximab was associated with poorer long?term survival (68% versus 76% at 5 years [P<0.001] and 49% versus 65% at 10 years [P<0.001], respectively). Basiliximab was associated with higher risk of death attributable to graft failure (P=0.013), but not death attributable to cardiovascular causes (P=0.444), infection (P=0.095), or malignancy (P=0.392). After multivariate analysis, use of basiliximab (versus use of anti?thymocyte globulin) remained significantly associated with all?cause mortality (hazard ratio, 1.27; 95% confidence interval, 1.02?1.57; P=0.030). Conclusions: In pediatric heart transplant patients, use of basiliximab for induction therapy was associated with an increased risk of mortality, when compared with those receiving anti?thymocyte globulin. äComparison of Basiliximab and Anti?Thymocyte Globulin as Induction The(epmc).pdf DeepDyve Pubget Overpricing